FDA Declines Breakthrough Therapy Status For Equillium's Itolizumab
24/4 15:50
(RTTNews) - Equillium, Inc. (EQ), a clinical-stage biotechnology company, Thursday said that the U.S. Food and Drug Administration (FDA) declined to grant Breakthrough Therapy designation for itolizumab for the treatment of acute graft-versus-host disease (aGVHD) based on the EQU...